Citations (90)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Alessandra Audia, Gregory Bannish, Rachel Bunting & Chelsea Riveley. (2022) Flow cytometry and receptor occupancy in immune-oncology. Expert Opinion on Biological Therapy 22:1, pages 87-94.
Read now
Read now
David M. Richards, Julian P. Sefrin, Christian Gieffers, Oliver Hill & Christian Merz. (2020) Concepts for agonistic targeting of CD40 in immuno-oncology. Human Vaccines & Immunotherapeutics 16:2, pages 377-387.
Read now
Read now
Anna Korycka-Wołowiec, Dariusz Wołowiec & Tadeusz Robak. (2017) The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opinion on Drug Safety 16:2, pages 185-201.
Read now
Read now
Gregory L. Beatty, Yan Li & Kristen B. Long. (2017) Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Review of Anticancer Therapy 17:2, pages 175-186.
Read now
Read now
Marius Stiefelhagen, Carola Gigel, Elena Vasyutina, Michael Möllmann, Alexandra Breuer, Petra Mayer, Jan Dürig & Marco Herling. (2016) Activity of the CD40 antagonistic antibody lucatumumab – insights from CLL-niche mimicking xenografts and fludarabine combinations. Leukemia & Lymphoma 57:9, pages 2235-2238.
Read now
Read now
Audrey Mohr, Yves Renaudineau, Cristina Bagacean, Jacques-Olivier Pers, Christophe Jamin & Anne Bordron. (2016) Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia. OncoImmunology 5:5.
Read now
Read now
Michael Doubek & Michal Šmída. (2015) Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. Expert Review of Hematology 8:6, pages 743-764.
Read now
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Read now
Michele Merli, Andrea Ferrario, Margherita Maffioli, Luca Arcaini & Francesco Passamonti. (2015) Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Investigational Drugs 24:7, pages 897-912.
Read now
Read now
Jamie Honeychurch, Eleanor J Cheadle, Simon J Dovedi & Timothy M Illidge. (2015) Immuno-regulatory antibodies for the treatment of cancer. Expert Opinion on Biological Therapy 15:6, pages 787-801.
Read now
Read now
Barbara Zarzycka, Gerry A F Nicolaes & Esther Lutgens. (2015) Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis. Expert Review of Clinical Pharmacology 8:3, pages 297-313.
Read now
Read now
Tadeusz Robak. (2014) Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Review of Hematology 7:6, pages 841-857.
Read now
Read now
Sufia Butt Hassan, Jesper Freddie Sørensen, Barbara Nicola Olsen & Anders Elm Pedersen. (2014) Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacology and Immunotoxicology 36:2, pages 96-104.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Alexander Eggermont, Jérôme Galon, Wolf Hervé Fridman, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:2.
Read now
Read now
Alessandra Ferrajoli. (2012) Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia. Leukemia & Lymphoma 53:11, pages 2093-2094.
Read now
Read now
Articles from other publishers (75)
Domenico Ribatti. (2023) Mast Cells and Resistance to Immunotherapy in Cancer. Archivum Immunologiae et Therapiae Experimentalis 71:1.
Crossref
Crossref
Isabell Lang, Olena Zaitseva & Harald Wajant. (2022) FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies. International Journal of Molecular Sciences 23:21, pages 12869.
Crossref
Crossref
Thierry D. Flandre, Keith G. Mansfield, Pascal J. Espié, Tina Rubic-Schneider & Peter Ulrich. (2022) Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study. Toxicologic Pathology 50:5, pages 712-724.
Crossref
Crossref
Pedram Moeini & Paulina Niedźwiedzka-Rystwej. (2021) Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment. International Journal of Molecular Sciences 22:13, pages 7239.
Crossref
Crossref
Raquel Delgado, Karoline Kielbassa, Johanna ter Burg, Christian Klein, Christine Trumpfheller, Koen de Heer, Arnon P. Kater & Eric Eldering. (2021) Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers 13:12, pages 3084.
Crossref
Crossref
Benjamin Wolfson, S. Elizabeth Franks & James W. Hodge. (2021) Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines 9:5, pages 509.
Crossref
Crossref
Tiffany Davia Ricketts, Nestor Prieto-Dominguez, Pramod Sreerama Gowda & Eric Ubil. (2021) Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. Frontiers in Immunology 12.
Crossref
Crossref
Fabrizio Marcucci & Cristiano Rumio. (2021) Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer. Cells 10:4, pages 872.
Crossref
Crossref
Clifford M. Csizmar & Stephen M. Ansell. (2021) Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. International Journal of Molecular Sciences 22:7, pages 3302.
Crossref
Crossref
TingTing Tang, Xiang Cheng, Billy Truong, LiZhe Sun, XiaoFeng Yang & Hong Wang. (2021) Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacology & Therapeutics 219, pages 107709.
Crossref
Crossref
Federico VOZELLA, Francesca FAZIO, Gianfranco LAPIETRA, Maria T. PETRUCCI, Giovanni MARTINELLI & Claudio CERCHIONE. (2021) Monoclonal antibodies in multiple myeloma. Panminerva Medica 63:1.
Crossref
Crossref
Iris de Weerdt, Roeland Lameris, George L. Scheffer, Jana Vree, Renate de Boer, Anita G. Stam, Rieneke van de Ven, Mark-David Levin, Steven T. Pals, Rob C. Roovers, Paul W.H.I. Parren, Tanja D. de Gruijl, Arnon P. Kater & Hans J. van der Vliet. (2021) A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies. Cancer Immunology Research 9:1, pages 50-61.
Crossref
Crossref
John W. Myers, George E. Peoples & Guy T. Clifton. 2021. Cancer Immunology. Cancer Immunology
85
128
.
Yongheng Shu & Ping Cheng. (2020) Targeting tumor-associated macrophages for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:2, pages 188434.
Crossref
Crossref
Haiying Lu, Qiaodan Zhou, Jun He, Zhongliang Jiang, Cheng Peng, Rongsheng Tong & Jianyou Shi. (2020) Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Anne Bordron, Cristina Bagacean, Adrian Tempescul, Christian Berthou, Eléonore Bettacchioli, Sophie Hillion & Yves Renaudineau. (2019) Complement System: a Neglected Pathway in Immunotherapy. Clinical Reviews in Allergy & Immunology 58:2, pages 155-171.
Crossref
Crossref
Felice Pepe & Veronica Balatti. (2020) Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. Journal of Clinical Medicine 9:2, pages 593.
Crossref
Crossref
Stefania Crisci, Raffaele Di Francia, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Rosaria De Filippi, Massimiliano Berretta, Paola Rossi & Antonio Pinto. (2019) Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Frontiers in Oncology 9.
Crossref
Crossref
Li Lu, Xi Wang, Ao Zhang, Fei Huang, Yongjia Yan, Weidong Li & Weihua Fu. (2019) Selection and expression of CD40 single chain variable fragment by phage display and evaluation of tumor specific immune activation. International Immunopharmacology 71, pages 224-232.
Crossref
Crossref
Ali A. Maawy & Fumito Ito. 2019. Immune Checkpoint Inhibitors in Cancer. Immune Checkpoint Inhibitors in Cancer
227
243
.
Christian Merz, Jaromir Sykora, Viola Marschall, David M. Richards, Karl Heinonen, Mauricio Redondo Müller, Meinolf Thiemann, Tim Schnyder, Harald Fricke, Oliver Hill & Christian Gieffers. (2018) The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells. Journal of Immunotherapy 41:9, pages 385-398.
Crossref
Crossref
Peter Ulrich, Thierry Flandre, Pascal Espie, Denise Sickert, Tina Rubic-Schneider, David A Shaw & James S Rush. (2018) Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus Monkeys. Toxicological Sciences.
Crossref
Crossref
Dana A. Emerson & William L. Redmond. (2018) Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. BioDrugs 32:3, pages 221-231.
Crossref
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Crossref
Lisette Bronswijk-Deddens. 2018. Epitope Mapping Protocols. Epitope Mapping Protocols
207
220
.
Iulia Giuroiu & Jeffrey Weber. (2017) Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy. The Cancer Journal 23:1, pages 23-31.
Crossref
Crossref
David Kotlyar & Anthony Leonardi. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets
31
42
.
Ensaf Al-Hujaily, Robyn Oldham, Parameswaran Hari & Jeffrey Medin. (2016) Development of Novel Immunotherapies for Multiple Myeloma. International Journal of Molecular Sciences 17:9, pages 1506.
Crossref
Crossref
Michael T. Tees & Lubomir Sokol. (2016) Novel Immunotherapies for B-Cell Lymphomas and Leukemias. American Journal of Therapeutics 23:5, pages e1157-e1181.
Crossref
Crossref
Marta Bagnati, Babatunji W Ogunkolade, Catriona Marshall, Carmen Tucci, Katie Hanna, Tania A Jones, Marco Bugliani, Belinda Nedjai, Paul W Caton, Julius Kieswich, Muhammed M Yaqoob, Graham R Ball, Piero Marchetti, Graham A Hitman & Mark D Turner. (2016) Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation. Cell Death & Disease 7:8, pages e2329-e2329.
Crossref
Crossref
Jennifer Edelmann & John G Gribben. (2016) Obinutuzumab for the treatment of indolent lymphoma. Future Oncology 12:15, pages 1769-1781.
Crossref
Crossref
Matthijs F. Jansen, Maurits R. Hollander, Niels van Royen, Anton J. Horrevoets & Esther Lutgens. (2016) CD40 in coronary artery disease: a matter of macrophages?. Basic Research in Cardiology 111:4.
Crossref
Crossref
Tadeusz Robak, Jerzy Z. Blonski & Pawel Robak. (2016) Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Seminars in Oncology 43:2, pages 280-290.
Crossref
Crossref
Weiping ZouJedd D. WolchokLieping Chen. (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine 8:328.
Crossref
Crossref
Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, Carolina Schinke, Pankaj Mathur, Christoph J Heuck, Maurizio Zangari, Joshua Epstein, Shmuel Yaccoby, Niels Weinhold, Bart Barlogie & Frits van Rhee. (2016) Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. Immunotherapy 8:3, pages 367-384.
Crossref
Crossref
Djordje Atanackovic, Sabarinath V. Radhakrishnan, Neelam Bhardwaj & Tim Luetkens. (2016) Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. British Journal of Haematology 172:5, pages 685-698.
Crossref
Crossref
Ola Sternebring, Lene Alifrangis, Toke Folke Christensen, Hong Ji, Anne Charlotte Hegelund & Carl-Magnus Högerkorp. (2016) A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development. Cytometry Part B: Clinical Cytometry 90:2, pages 220-229.
Crossref
Crossref
Ciara L. Freeman & John G. Gribben. (2016) Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Current Hematologic Malignancy Reports 11:1, pages 29-36.
Crossref
Crossref
David Kotlyar & Anthony Leonardi. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets
1
12
.
M. Bäck, C. Weber & E. Lutgens. (2015) Regulation of atherosclerotic plaque inflammation. Journal of Internal Medicine 278:5, pages 462-482.
Crossref
Crossref
Preetesh Jain & Susan O'Brien. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research
130
144
.
Marzenna Blonska, Nitin K. Agarwal & Francisco Vega. (2015) Shaping of the tumor microenvironment: Stromal cells and vessels. Seminars in Cancer Biology 34, pages 3-13.
Crossref
Crossref
Elizabeth A. Thompson, Frank Liang, Gustaf Lindgren, Kerrie J. Sandgren, Kylie M. Quinn, Patricia A. Darrah, Richard A. Koup, Robert A. Seder, Ross M. Kedl & Karin Loré. (2015) Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates. The Journal of Immunology 195:3, pages 1015-1024.
Crossref
Crossref
Martine A. Boks, Wendy W.J. Unger, Steef Engels, Martino Ambrosini, Yvette van Kooyk & Regina Luttge. (2015) Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. International Journal of Pharmaceutics 491:1-2, pages 375-383.
Crossref
Crossref
Antonino CarboneClifford Blieden, Nitin Kumar Agarwal & Francisco Vega. 2015. Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 1). Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 1)
34
50
.
Ghada S. Hassan, John Stagg & Walid Mourad. (2015) Role of CD154 in cancer pathogenesis and immunotherapy. Cancer Treatment Reviews 41:5, pages 431-440.
Crossref
Crossref
Stanley C Jordan, Jua Choi & Ashley Vo. (2015) Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy 7:4, pages 377-398.
Crossref
Crossref
Kyle Crassini. (2015) Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World Journal of Clinical Cases 3:8, pages 694.
Crossref
Crossref
Louis M. Weiner & Rishi Surana. 2015. The Molecular Basis of Cancer. The Molecular Basis of Cancer
683
694.e3
.
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs
561
593
.
Guy T. Clifton, Elizabeth A. Mittendorf & George E. Peoples. 2015. Cancer Immunology. Cancer Immunology
87
129
.
Tejas Suresh, Lisa X Lee, Jitesh Joshi & Stefan K Barta. (2014) New antibody approaches to lymphoma therapy. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
Ralph E. Vatner, Benjamin T. Cooper, Claire Vanpouille-Box, Sandra Demaria & Silvia C. Formenti. (2014) Combinations of Immunotherapy and Radiation in Cancer Therapy. Frontiers in Oncology 4.
Crossref
Crossref
Monika Podhorecka, Justyna Markowicz, Agnieszka Szymczyk & Johannes Pawlowski. (2014) Target Therapy in Hematological Malignances: New Monoclonal Antibodies. International Scholarly Research Notices 2014, pages 1-16.
Crossref
Crossref
Aleksandra Korniluk, Halina Kemona & Violetta Dymicka-Piekarska. (2014) Multifunctional CD40L: pro- and anti-neoplastic activity. Tumor Biology 35:10, pages 9447-9457.
Crossref
Crossref
Stephanie R Jackson, Jinyun Yuan & Ryan M Teague. (2014)
Targeting CD8
+
T-cell tolerance for cancer immunotherapy
. Immunotherapy 6:7, pages 833-852.
Crossref
Crossref
Christian P. Pallasch & Michael Hallek. (2014) Incorporating Targeted Agents Into Future Therapy of Chronic Lymphocytic Leukemia. Seminars in Hematology 51:3, pages 235-248.
Crossref
Crossref
Thomas Schirrmann, Miriam Steinwand, Xenia Wezler, Andre ten Haaf, Mehmet K. Tur & Stefan Barth. (2013) CD30 as a Therapeutic Target for Lymphoma. BioDrugs 28:2, pages 181-209.
Crossref
Crossref
Sindy Liao-Chan, Joseph Zachwieja, Steven Gomez, Dana Duey, John Lippincott & Jan-Willem Theunissen. (2014) Monoclonal antibody binding-site diversity assessment with a cell-based clustering assay. Journal of Immunological Methods 405, pages 1-14.
Crossref
Crossref
Gerardo Ferrer, Rosa Bosch, Kate Hodgson, Rut Tejero, Gael Roué, Dolors Colomer, Emili Montserrat & Carol Moreno. (2014) B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. British Journal of Haematology 164:4, pages 570-578.
Crossref
Crossref
Michelle Fanale, Sarit Assouline, John Kuruvilla, Philippe Solal-Céligny, Dae S. Heo, Gregor Verhoef, Paolo Corradini, Jeremy S. Abramson, Fritz Offner, Andreas Engert, Martin J. S. Dyer, Daniel Carreon, Brett Ewald, Johan Baeck, Anas Younes & Arnold S. Freedman. (2014) Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. British Journal of Haematology 164:2, pages 258-265.
Crossref
Crossref
Brian A. Baldo. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
561
590
.
Marcus Remer, Ann White, Martin Glennie, Aymen Al-Shamkhani & Peter Johnson. 2017. Cancer Vaccines. Cancer Vaccines
165
207
.
Michael Hallek. (2013) Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematology 2013:1, pages 138-150.
Crossref
Crossref
Michael Hallek. (2013) Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 122:23, pages 3723-3734.
Crossref
Crossref
Tomasz Maj, Shuang Wei, Ted Welling & Weiping Zou. (2013) T Cells and Costimulation in Cancer. The Cancer Journal 19:6, pages 473-482.
Crossref
Crossref
Michael Hallek. (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology 88:9, pages 803-816.
Crossref
Crossref
Chern Siang Lee, Mark Cragg, Martin Glennie & Peter Johnson. (2013) Novel antibodies targeting immune regulatory checkpoints for cancer therapy. British Journal of Clinical Pharmacology 76:2, pages 233-247.
Crossref
Crossref
Edwin Bremer. (2013) Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy. ISRN Oncology 2013, pages 1-25.
Crossref
Crossref
John C. Riches & John G. Gribben. (2013) Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America 27:2, pages 207-235.
Crossref
Crossref
Deborah M. Stephens & John C. Byrd. (2013) Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy. Hematology/Oncology Clinics of North America 27:2, pages 303-327.
Crossref
Crossref
Amy E Moran, Magdalena Kovacsovics-Bankowski & Andrew D Weinberg. (2013) The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Current Opinion in Immunology 25:2, pages 230-237.
Crossref
Crossref
Michael Croft, Chris A. Benedict & Carl F. Ware. (2013) Clinical targeting of the TNF and TNFR superfamilies. Nature Reviews Drug Discovery 12:2, pages 147-168.
Crossref
Crossref
Barry D. Hock, Liam J. Fernyhough, Sheryl M. Gough & Judith L. McKenzie. (2013) Clinical Significance of Plasma Levels of Soluble CD40 in Patients with Chronic Lymphocytic Leukemia. Open Journal of Blood Diseases 03:01, pages 1-5.
Crossref
Crossref
Tadeusz Robak. (2013) Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncology 9:1, pages 69-91.
Crossref
Crossref